J&J starts European COVID-19 vaccine roll-out
After a positive re-evaluation of J&Js COVID-19 vaccine by the European Medicines Agency (EMA), J&J has re-started to ship 55 million doses to the EU.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1191 entries already.
Entries by Thomas Gabrielczyk
Endeavour Medtech Growth II LP closes at $375m
/in News/by Thomas GabrielczykEndeavour Vision has announced the closing of its Heathtech fund Endeavour Medtech Growth II (EMG II) LP at US$375 million in capital commitments.
Record year for Swiss biotech industry
/in News/by Thomas GabrielczykThe Swiss biotech industry experienced a record investment in the pandemic year 2020, according to the new Swiss Biotech Report.
EU orders 100 million additional doses from Biontech
/in News/by Thomas GabrielczykThe European Union has exercised its option to order 100 million additional doses of BNT162b2 bringing its orders to 600 million doses at 14.70 per shot.
COVID-19: Study finds neutralising antibodies to disappear rapidly
/in News/by Thomas GabrielczykA new study on the persistence of neutralising antibodies to SARS-CoV-2 in the blood suggests that humoral immunity will drop 5 months after vaccination.
BioVersys gets 20m EIB loan to develop novel antibiotics
/in News/by Thomas GabrielczykSwiss BioVersys has received 20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.
C4X Discovery and Sanofi ink 414m IL-17A blocker R&D contract
/in News/by Thomas GabrielczykC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
Next-gen COVID-19 vaccine good in preclinical tests
/in News/by Thomas GabrielczykIntravacc has announced positive data for its nasal SARS-CoV-2 vaccine that embeds the viral spike antigen in bacterial Outer Membrane Vesicles (OMV)
EMA: AZD1222 causes serious rare ADEs
/in News/by Thomas GabrielczykIn a new statement, the EU regulatory authority EMA postulates that AstraZeneca’s vaccine causes serious deep vein thrombosis.
Targeting SARS-CoV-2 differently
/in News/by Thomas GabrielczykGerman structural biologists have identified seven compounds that neutralise SARS-CoV-2 by targeting Mpro, the virus main protease.